Exicure
XCURExicure, Inc. is a biotechnology company that has transitioned from developing proprietary nucleic acid therapies to exploring strategic growth through acquisitions and partnerships.
Earnings
Next report
Nov 12, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Exicure, Inc. is a biotechnology company that has transitioned from developing proprietary nucleic acid therapies to exploring strategic growth through acquisitions and partnerships. The company currently focuses on advancing clinical-stage oncology treatments through its acquired subsidiary and leveraging its status as a publicly traded entity to attract new business combinations. Its core value proposition lies in its clinical assets for blood cancer and its pursuit of value-generating transactions, particularly within the Asian and domestic markets.
Exicure is currently in a transitional state, moving from a research-focused organization to a strategic vehicle for business combinations while maintaining early-to-mid-stage clinical oncology assets.
FAQ
- What is Exicure's market cap?
- Exicure (XCUR) has a market capitalization of $6.1M and trades on NASDAQ.
- Who are Exicure's competitors?
- Exicure's key competitors include Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., GT Biopharma Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Exicure partner with?
- Exicure's notable partners include GPCR Therapeutics Inc, Bluejay Therapeutics, Inc., Flashpoint Therapeutics, Inc., and others.
- What subsidiaries does Exicure have?
- Exicure's subsidiaries include GPCR Therapeutics USA Inc., KC Creation Co., Ltd..
- Where is Exicure headquartered?
- Exicure is headquartered in United States of America and employs approximately 5 people. It has been publicly traded since 2018.